We did a thing! We have now created Monthly Newsletters!! Subscribe to our website for monthly updates on exciting things happening at BG Lab ! oncologybg.com/2025/11/03/mon… Brian Shkabari

This is a very comprehensive update on all the important sessions from Day 2 of ABC meeting.

In this new Medscape Medscape Oncology blog post, Bishal Gyawali, MD, PhD, FASCO highlights some positive changes he noticed in a couple of new clinical trials reported during #ESMO25. medscape.com/viewarticle/be…

I noted a progression in the reactions to your message at #ABC8 (applause) compared to ABC7. So important that profound knowledge on study design and its implications on treatment recommendations is heard. Thanks for your efforts in moving the field in the right direction.

Indeed. That’s a great observation. Thank you for pointing this out. I have also noticed this in recent years that more and more people are now seeing the problems that we have been pointing out for a long time. The amount of positive response I received yesterday, including

Empowering Oncologists Podcast – From Cancer Groundshots to Financial Toxicity to Common Sense to Personal Stories Bishal Gyawali, MD, PhD, FASCO Jasmine Kamboj, MD, FASCO oncodaily.com/voices/empower… #Cancer #Oncology #OncoDaily #Health #Medicine CancerWorld

In my new Medscape Oncology column, I have the opportunity to praise 2 RCTs for doing the right thing. Guess which RCTs they are! medscape.com/viewarticle/be… I hope I get these opportunities to praise cancer drug RCTs more often. BG Lab

How do oncologists in LMICs like India make treatment decisions? Join Bishal Gyawali, MD, PhD, FASCO and colleagues as they discuss quality of evidence, magnitude of benefit, drug prices, FDA approval status and clinical practice guidelines. oncologybg.com/2025/10/26/web…

I write in praise of 2 RCTs. Guess which 2 RCTs they are. medscape.com/viewarticle/be…

A proof of change 🥰

Bishal Gyawali, MD, PhD, FASCO Common Sense Oncology teach me a lot here

‼️New BG Lab paper! We looked at the availability + affordability + price variation of GI cancer medicines in Nepal. Prices can fluctuate +900% across hospitals and +400% within the same hospital…. ascopubs.org/doi/10.1200/GO… (also my first co-1st author pub! 😎)

Join Bishal Gyawali, MD, PhD, FASCO and colleagues as they discuss quality of evidence, magnitude of benefit, drug prices, FDA approval status and clinical practice guidelines for oncologists in LMICs like India. oncologybg.com/2025/10/26/web… OncoAlert #OncoAlert